Qurient Co., Ltd. (KOSDAQ:115180)

South Korea flag South Korea · Delayed Price · Currency is KRW
45,050
-1,550 (-3.33%)
At close: Mar 19, 2026
Market Cap1.82T +760.7%
Revenue (ttm)8.28B -5.4%
Net Income-24.72B
EPS-706.17
Shares Out40.41M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume447,737
Average Volume645,112
Open45,250
Previous Close46,600
Day's Range43,600 - 45,900
52-Week Range7,070 - 62,900
Beta0.77
RSI58.83
Earnings DateMar 24, 2026

About Qurient

Qurient Co., Ltd., a biotech company, engages in the research and development of drugs to address unmet medical needs in Korea and internationally. The company’s pipeline products include Q301, a topical 5LO inhibitor, which is in Phase II clinical trial for the treatment of atopic dermatitis; and Telacebec (Q203), Cyt bc1 Inhibitor, that is in Phase II to treat Mycobacterial Infections, such as tuberculosis/non-TBM. Its pipeline products also comprise Adrixetinib (Q702), an Axl/Mer/CSF1R Inhibitor, which completed phase I for the treatment of ... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2008
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 115180
Full Company Profile

Financial Performance

In 2024, Qurient's revenue was 9.18 billion, an increase of 1.64% compared to the previous year's 9.03 billion. Losses were -23.57 billion, 11.6% more than in 2023.

Financial Statements